The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST).

被引：0
|
作者：
Stillman, Ipek Ozer
Strand, Lauren N.
Chang, Jane
Mohamed, Ateesha F.
Fahrbach, Kyle
Freier, Katherine E. Tranbarger
机构：
[1] Evidera, Lexington, MA USA
[2] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[3] United BioSource Corp, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10557
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exploring the relation between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) via meta-analysis.
    Keyser, R. L.
    Freier, K. E. Tranbarger
    Hoaglin, D. C.
    Tzivelekis, S.
    Ozer-Stillman, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [3] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal Tumor
    Oezer-Stillman, Ipek
    Strand, Lauren
    Chang, Jane
    Mohamed, Ateesha F.
    Tranbarger-Freier, Katherine E.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (02) : 295 - 302
  • [5] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [6] Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib in the phase 3 GRID trial
    Kappeler, C.
    Wagner, A.
    Demetri, G. D. S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS
    Oh, Youjin
    Djunadi, Trie Arni
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Shah, Zunairah
    Park, Joo Hee
    Yoon, Sung Mi
    Duan, Richard
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1468 - A1469
  • [8] OVERALL SURVIVAL (OS) VERSUS PROGRESSION-FREE SURVIVAL (PFS): IS THERE A RATIONAL FOR REPLACING ONE OUTCOME FOR THE OTHER?
    Teich, V
    Fernandes, R. A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A863 - A863
  • [9] Effect of the quality of the methodology on the relationship between progression-free survival (PFS) and overall survival (OS) in advanced colorectal cancer clinical trials.
    Garcia-Albeniz, X.
    Carrera, G.
    Feliu, J.
    Aparicio, J.
    Torres, F.
    Maurel, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345